ABBV vs NVS stock comparison
AbbVie vs. Novartis · data as of November 13, 2026
AbbVie (ABBV) has a market value of about $521.5B, Novartis (NVS) about $306.3B. Over their latest twelve months AbbVie had revenue of $66.0B and Novartis $57.4B.
On our five checks Novartis scores higher: 2.0 out of 5 (weak) against 1.8 (weak).
By area, the stronger company is AbbVie on future growth; Novartis on track record; Novartis on financial health; AbbVie on shareholder returns.
Novartis is cheaper on earnings (P/E 30.7 vs. 50.8), while AbbVie grew revenue faster over five years (5.9% vs. 2.3% a year).
AbbVie leads on 8 of the compared lines and Novartis on 15.
Side by side
| ABBV | NVS | |
|---|---|---|
| Size and price | ||
| Market cap | $521.5B | $306.3B |
| Share price | $295.03 | $160.50 |
| Score | ||
| Overall score (of 5) | 1.8 | 2.0 |
| Value | 0 | 0 |
| Future growth | 1 | 0 |
| Track record | 2 | 4 |
| Financial health | 2 | 3 |
| Shareholder returns | 4 | 3 |
| Valuation | ||
| P/E (TTM) | 50.8 | 30.7 |
| Forward P/E | 19.1 | 17.0 |
| Price / free cash flow | 27.6 | 21.9 |
| Price / sales | 7.9 | 5.3 |
| EV / EBITDA | 19.8 | 14.4 |
| PEG | — | 2.02 |
| DCF value vs. price | −20% | −9% |
| Business | ||
| Revenue | $66.0B | $57.4B |
| Net income | $10.3B | $10.0B |
| Free cash flow | $18.9B | $14.0B |
| Net margin | 15.7% | 17.5% |
| Gross margin (5-yr avg.) | 68.3% | 76.4% |
| ROIC (5-yr avg.) | 15.3% | 14.1% |
| Growth | ||
| Revenue growth (1 yr) | 8.6% | 8.4% |
| Revenue growth (5 yrs, per year) | 5.9% | 2.3% |
| EPS growth (5 yrs, per year) | -2.8% | 15.2% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$61.5B | -$39.3B |
| Dividend yield | 2.35% | 2.95% |
| Shareholder yield | 2.5% | 6.0% |
| Analysts | ||
| Upside to average target | +6% | −2% |
| Consensus rating | Buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: ABBV TTM to September 30, 2026, NVS TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, AbbVie or Novartis?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Novartis scores 2.0 out of 5 and AbbVie 1.8; the table shows where each one is stronger.
Is AbbVie cheaper than Novartis?
On trailing earnings, Novartis trades at a P/E of 30.7 and AbbVie at 50.8, so Novartis is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, AbbVie or Novartis?
Over five years AbbVie grew revenue about 5.9% a year and Novartis about 2.3% a year.
Which pays a higher dividend?
AbbVie yields 2.35% and Novartis 2.95%.
Full AbbVie analysis → Full Novartis analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.